Sax, P.E., DeJesus, E., Mills, A., Zolopa, A., Cohen, C., Wohl, D., Gallant, J., Liu, H.C., Zhong, L., Yale, K., White, K., Kearney, B.P., Szwarcberg, J., Quirk, E. and Cheng, A.K. (2012) Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir versus Co-Formulated Efavirenz, Emtricitabine, and Tenofovir for Initial Treatment of HIV-1 Infection: a Randomised, Double-Blind, Phase 3 Trial, Analysis of Results after 48 Weeks. The Lancet, 379, 2439-2448.

has been cited by the following article:

• TITLE: Estimated Binding Energies of Drug-Like and Nondrug-Like Molecules in the Active Site of HIV-1 Integrase, 1BIS.pdb, and Two Mutant Models: Y143R and N155H

  AUTHORS: Julie B. Ealy, Noorhaan Abouomar, Justin Cogan, Paolo Flauta, Liliana Nassar, Matthew Mekolochik, Sarah Ramzy, Christopher Shannon, Habib Yazgi

  KEYWORDS: Lipinski’s “Rule of Five”, Drug-Like and Nondrug-Like Molecules, HIV-1 Integrase, Estimated Binding Energy, Pharmacophore

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.8 No.5, May 27, 2017

  ABSTRACT: Lipinski’s “Rule of Five” was introduced for predicting oral bioavailability to describe drug-like molecules. For the purpose of this research the rules were used to separate potential inhibitors of HIV-1 integrase (1BIS.pdb) into two groups: drug-like and nondrug-like. If one of Lipinski’s “Rule of Five” was not followed the potential inhibitor was classified as nondrug-like. Thirty molecules were identified from the literature, twenty-four drug-like and six nondrug-like, that were docked into the active site of 1BIS.pdb (considered the non-mutated protein) and two mutant models, Y143R and N155H. These are two of the mutations that have led to increased resistance to HIV-1 integrase drugs such as raltegravir and elvitegravir. The computational software, ICM-Pro (Molsoft L.L.C.), was used to determine the estimated binding energy (EBE) of the drug/protein complex. It was found that the nondrug-like molecules generally had a more negative EBE, that is, tighter binding with 1BIS. pdb, though there were several exceptions in the drug-like group. With the protein mutant model Y143R, the majority of drug-like (58%) and nondrug-like molecules (67%) had tighter binding. However, for the mutant model N155H, there was the same percent (46%) of drug-like molecules with tighter binding with the mutant model as with 1BIS.pdb. The drug-like molecules were used when there was a ≥1 kcal/mole difference between 1BIS.pdb and either of the two mutant models to suggest a pharmacophore with structural characteristics for an HIV-1 integrase inhibitor.